AURINIA PHARMACEUTICALS INC (AUPH) Fundamental Analysis & Valuation

NASDAQ:AUPH • CA05156V1022

Current stock price

14.08 USD
-0.39 (-2.7%)
At close:
14.14 USD
+0.06 (+0.43%)
After Hours:

This AUPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. AUPH Profitability Analysis

1.1 Basic Checks

  • In the past year AUPH was profitable.
  • In the past year AUPH had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: AUPH reported negative net income in multiple years.
  • In multiple years AUPH reported negative operating cash flow during the last 5 years.
AUPH Yearly Net Income VS EBIT VS OCF VS FCFAUPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 38.21%, AUPH belongs to the top of the industry, outperforming 98.26% of the companies in the same industry.
  • AUPH's Return On Equity of 49.40% is amongst the best of the industry. AUPH outperforms 98.46% of its industry peers.
  • The Return On Invested Capital of AUPH (12.51%) is better than 94.98% of its industry peers.
Industry RankSector Rank
ROA 38.21%
ROE 49.4%
ROIC 12.51%
ROA(3y)8.34%
ROA(5y)-6.25%
ROE(3y)10.1%
ROE(5y)-6.84%
ROIC(3y)N/A
ROIC(5y)N/A
AUPH Yearly ROA, ROE, ROICAUPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • AUPH's Profit Margin of 101.47% is amongst the best of the industry. AUPH outperforms 98.65% of its industry peers.
  • AUPH has a better Operating Margin (37.65%) than 97.30% of its industry peers.
  • AUPH's Gross Margin of 88.46% is amongst the best of the industry. AUPH outperforms 90.15% of its industry peers.
  • AUPH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 37.65%
PM (TTM) 101.47%
GM 88.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5YN/A
AUPH Yearly Profit, Operating, Gross MarginsAUPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AUPH Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AUPH is still creating some value.
  • The number of shares outstanding for AUPH has been reduced compared to 1 year ago.
  • Compared to 5 years ago, AUPH has more shares outstanding
  • AUPH has a better debt/assets ratio than last year.
AUPH Yearly Shares OutstandingAUPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
AUPH Yearly Total Debt VS Total AssetsAUPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • AUPH has an Altman-Z score of 7.05. This indicates that AUPH is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.05, AUPH is in the better half of the industry, outperforming 77.03% of the companies in the same industry.
  • The Debt to FCF ratio of AUPH is 0.51, which is an excellent value as it means it would take AUPH, only 0.51 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of AUPH (0.51) is better than 95.56% of its industry peers.
  • AUPH has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.09, AUPH is not doing good in the industry: 61.97% of the companies in the same industry are doing better.
  • Although AUPH's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.51
Altman-Z 7.05
ROIC/WACC1.59
WACC7.89%
AUPH Yearly LT Debt VS Equity VS FCFAUPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 5.25 indicates that AUPH has no problem at all paying its short term obligations.
  • The Current ratio of AUPH (5.25) is comparable to the rest of the industry.
  • A Quick Ratio of 4.76 indicates that AUPH has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.76, AUPH perfoms like the industry average, outperforming 56.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.25
Quick Ratio 4.76
AUPH Yearly Current Assets VS Current LiabilitesAUPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. AUPH Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 800.00% over the past year.
  • The Revenue has grown by 20.38% in the past year. This is a very strong growth!
  • AUPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.39% yearly.
EPS 1Y (TTM)800%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2500%
Revenue 1Y (TTM)20.38%
Revenue growth 3Y28.31%
Revenue growth 5Y41.39%
Sales Q2Q%28.81%

3.2 Future

  • AUPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.23% yearly.
  • The Revenue is expected to grow by 13.00% on average over the next years. This is quite good.
EPS Next Y1.75%
EPS Next 2Y10.95%
EPS Next 3Y17.04%
EPS Next 5Y9.23%
Revenue Next Year16.02%
Revenue Next 2Y15.84%
Revenue Next 3Y16.09%
Revenue Next 5Y13%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AUPH Yearly Revenue VS EstimatesAUPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AUPH Yearly EPS VS EstimatesAUPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. AUPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 17.38, which indicates a rather expensive current valuation of AUPH.
  • 93.82% of the companies in the same industry are more expensive than AUPH, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 25.79. AUPH is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 17.08 indicates a rather expensive valuation of AUPH.
  • AUPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 95.17% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AUPH to the average of the S&P500 Index (23.80), we can say AUPH is valued slightly cheaper.
Industry RankSector Rank
PE 17.38
Fwd PE 17.08
AUPH Price Earnings VS Forward Price EarningsAUPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AUPH is valued cheaply inside the industry as 96.53% of the companies are valued more expensively.
  • 96.91% of the companies in the same industry are more expensive than AUPH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.83
EV/EBITDA 10.14
AUPH Per share dataAUPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AUPH does not grow enough to justify the current Price/Earnings ratio.
  • AUPH has a very decent profitability rating, which may justify a higher PE ratio.
  • AUPH's earnings are expected to grow with 17.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)9.94
PEG (5Y)N/A
EPS Next 2Y10.95%
EPS Next 3Y17.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AUPH Dividend Analysis

5.1 Amount

  • AUPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AUPH Fundamentals: All Metrics, Ratios and Statistics

AURINIA PHARMACEUTICALS INC

NASDAQ:AUPH (3/18/2026, 8:00:01 PM)

After market: 14.14 +0.06 (+0.43%)

14.08

-0.39 (-2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-11
Inst Owners55.01%
Inst Owner Change8.68%
Ins Owners1.67%
Ins Owner Change0.9%
Market Cap1.87B
Revenue(TTM)283.06M
Net Income(TTM)287.20M
Analysts78.46
Price Target17.05 (21.09%)
Short Float %7.87%
Short Ratio9.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.29%
Min EPS beat(2)17.65%
Max EPS beat(2)40.93%
EPS beat(4)4
Avg EPS beat(4)30.6%
Min EPS beat(4)6.95%
Max EPS beat(4)56.86%
EPS beat(8)8
Avg EPS beat(8)116.68%
EPS beat(12)11
Avg EPS beat(12)87.01%
EPS beat(16)14
Avg EPS beat(16)70.98%
Revenue beat(2)2
Avg Revenue beat(2)3.92%
Min Revenue beat(2)1.01%
Max Revenue beat(2)6.84%
Revenue beat(4)3
Avg Revenue beat(4)3.78%
Min Revenue beat(4)-0.48%
Max Revenue beat(4)7.75%
Revenue beat(8)6
Avg Revenue beat(8)4.25%
Revenue beat(12)9
Avg Revenue beat(12)8.35%
Revenue beat(16)13
Avg Revenue beat(16)10.05%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.85%
EPS NQ rev (3m)-0.85%
EPS NY rev (1m)-13.58%
EPS NY rev (3m)-9.55%
Revenue NQ rev (1m)3.01%
Revenue NQ rev (3m)3.01%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE 17.38
Fwd PE 17.08
P/S 6.61
P/FCF 13.83
P/OCF 13.8
P/B 3.22
P/tB 3.24
EV/EBITDA 10.14
EPS(TTM)0.81
EY5.75%
EPS(NY)0.82
Fwd EY5.85%
FCF(TTM)1.02
FCFY7.23%
OCF(TTM)1.02
OCFY7.25%
SpS2.13
BVpS4.37
TBVpS4.34
PEG (NY)9.94
PEG (5Y)N/A
Graham Number8.93
Profitability
Industry RankSector Rank
ROA 38.21%
ROE 49.4%
ROCE 16.2%
ROIC 12.51%
ROICexc 31.66%
ROICexgc 32.13%
OM 37.65%
PM (TTM) 101.47%
GM 88.46%
FCFM 47.84%
ROA(3y)8.34%
ROA(5y)-6.25%
ROE(3y)10.1%
ROE(5y)-6.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.63%
GM growth 5YN/A
F-Score7
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.51
Debt/EBITDA 0.42
Cap/Depr 1.3%
Cap/Sales 0.09%
Interest Coverage 250
Cash Conversion 107.66%
Profit Quality 47.15%
Current Ratio 5.25
Quick Ratio 4.76
Altman-Z 7.05
F-Score7
WACC7.89%
ROIC/WACC1.59
Cap/Depr(3y)2.97%
Cap/Depr(5y)14.79%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)800%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2500%
EPS Next Y1.75%
EPS Next 2Y10.95%
EPS Next 3Y17.04%
EPS Next 5Y9.23%
Revenue 1Y (TTM)20.38%
Revenue growth 3Y28.31%
Revenue growth 5Y41.39%
Sales Q2Q%28.81%
Revenue Next Year16.02%
Revenue Next 2Y15.84%
Revenue Next 3Y16.09%
Revenue Next 5Y13%
EBIT growth 1Y478.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y206.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y205.62%
OCF growth 3YN/A
OCF growth 5YN/A

AURINIA PHARMACEUTICALS INC / AUPH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AURINIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 6 / 10 to AUPH.


What is the valuation status of AURINIA PHARMACEUTICALS INC (AUPH) stock?

ChartMill assigns a valuation rating of 6 / 10 to AURINIA PHARMACEUTICALS INC (AUPH). This can be considered as Fairly Valued.


Can you provide the profitability details for AURINIA PHARMACEUTICALS INC?

AURINIA PHARMACEUTICALS INC (AUPH) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for AUPH stock?

The Price/Earnings (PE) ratio for AURINIA PHARMACEUTICALS INC (AUPH) is 17.38 and the Price/Book (PB) ratio is 3.22.


Can you provide the expected EPS growth for AUPH stock?

The Earnings per Share (EPS) of AURINIA PHARMACEUTICALS INC (AUPH) is expected to grow by 1.75% in the next year.